The earnings call presented a strong performance with positive revenue growth, especially in Cardiovascular and Neuromodulation segments. The decision to spin off the Diabetes business is seen as a strategic move to focus on higher-margin growth areas. However, concerns about tariff impacts and currency headwinds were noted.

Company Guidance -

Q1 2026

During Medtronic's fiscal year 2025 fourth-quarter earnings call, the company reported a strong 5.4% organic revenue growth, with significant contributions from its Cardiovascular portfolio, which grew by 8%, and double-digit growth in Neuromodulation and Diabetes. The company achieved a high single-digit operating profit and low double-digit EPS growth, with EPS increasing 11% to $1.62 for the quarter. Medtronic announced its plan to separate the Diabetes business into a standalone public company via a capital market separation, aiming for a tax-free impact on shareholders and anticipating improvements in gross and operating margins by 50 and 100 basis points, respectively. For fiscal year 2026, Medtronic expects organic revenue growth of approximately 5% and EPS growth of about 4%, excluding tariffs. The company also highlighted its ongoing strategic focus on high-margin growth markets and new innovations, such as its Cardiac Ablation Solutions, which grew nearly 30%, and plans for the US launch of its Hugo robot and Symplicity hypertension procedure.

Strong Revenue Growth

The company reported a 5.4% organic revenue growth in Q4, with notable acceleration in Cardiovascular (8%), Neuromodulation, and Diabetes segments.

Cardiac Ablation Solutions Surge

Cardiac Ablation Solutions grew nearly 30%, driven by high demand for Affera PFA products and the Sphere-9 focal catheter.

Neuromodulation Leads Market

Neuromodulation grew 10%, with a 12% increase in Pain Stim and 15% growth in the US, maintaining the number one global position in SCS.

Diabetes Segment Growth

The Diabetes segment achieved 12% growth, marking the sixth consecutive quarter of double-digit growth, with strong contributions from the MiniMed 780G and Simplera Sync sensor.

Significant Operational Leverage

The company achieved high single-digit operating profit and low double-digit EPS growth, with Q4 EPS growth of 11%.

Portfolio Milestones

Two businesses, CAS and ENT, reached $1 billion in annual revenue, joining ten other businesses in this category.

Separation of Diabetes Business

The decision to separate the Diabetes business into a standalone public company is seen as a strategic move for focused growth and investment.

Medtronic (MDT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MDT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 19, 2025	2026 (Q1)	1.23 / -	1.23	―	―	―
May 21, 2025	2025 (Q4)	1.58 / 1.62	1.46	10.96% (+0.16)
Feb 18, 2025	2025 (Q3)	1.36 / 1.39	1.3	6.92% (+0.09)
Nov 19, 2024	2025 (Q2)	1.25 / 1.26	1.25	0.80% (+0.01)
Aug 20, 2024	2025 (Q1)	1.20 / 1.23	1.2	2.50% (+0.03)
May 23, 2024	2024 (Q4)	1.45 / 1.46	1.57	-7.01% (-0.11)
Feb 20, 2024	2024 (Q3)	1.26 / 1.30	1.3	0.00% (0.00)
Nov 21, 2023	2024 (Q2)	1.18 / 1.25	1.3	-3.85% (-0.05)
Aug 22, 2023	2024 (Q1)	1.11 / 1.20	1.13	6.19% (+0.07)
May 25, 2023	2023 (Q4)	1.55 / 1.57	1.52	3.29% (+0.05)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MDT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 21, 2025	$85.66	$83.71	-2.28%
Feb 18, 2025	$91.32	$84.69	-7.26%
Nov 19, 2024	$85.44	$82.92	-2.95%
Aug 20, 2024	$82.10	$82.64	+0.66%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.